drugset / Trial / NCT02562599

Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin

NCT02562599

Phase 2 Completed 60 enrolled Hubei Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of raltitrexed and cisplatin neoadjuvant chemotherapy followed by concurrent radiotherapy with raltitrexed and cisplatin in patients with locally advanced nasopharyngeal carcinoma.

Timeline

Start
2015-08
Primary completion
2016-12
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Raltitrexed Small molecule 2.5 mg/m2 Intravenous